Teleflex (TFX) vs. Its Peers Financial Survey

Teleflex (NYSE: TFX) is one of 104 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it contrast to its competitors? We will compare Teleflex to related companies based on the strength of its dividends, analyst recommendations, valuation, risk, profitability, earnings and institutional ownership.

Volatility & Risk

Teleflex has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500. Comparatively, Teleflex’s competitors have a beta of 0.80, suggesting that their average share price is 20% less volatile than the S&P 500.

Insider and Institutional Ownership

90.9% of Teleflex shares are held by institutional investors. Comparatively, 47.1% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 2.6% of Teleflex shares are held by insiders. Comparatively, 15.4% of shares of all “Surgical & medical instruments” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Teleflex and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Teleflex 7.11% 16.46% 6.97%
Teleflex Competitors -62.26% -47.35% -18.28%

Earnings and Valuation

This table compares Teleflex and its competitors gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Teleflex $2.15 billion $152.53 million 31.25
Teleflex Competitors $1.54 billion $111.80 million -144.37

Teleflex has higher revenue and earnings than its competitors. Teleflex is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Dividends

Teleflex pays an annual dividend of $1.36 per share and has a dividend yield of 0.5%. Teleflex pays out 16.2% of its earnings in the form of a dividend. As a group, “Surgical & medical instruments” companies pay a dividend yield of 1.2% and pay out 32.7% of their earnings in the form of a dividend.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Teleflex and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Teleflex 0 4 6 0 2.60
Teleflex Competitors 492 1883 3745 115 2.56

Teleflex presently has a consensus target price of $280.67, suggesting a potential upside of 6.91%. As a group, “Surgical & medical instruments” companies have a potential upside of 9.90%. Given Teleflex’s competitors higher probable upside, analysts plainly believe Teleflex has less favorable growth aspects than its competitors.

Summary

Teleflex beats its competitors on 10 of the 15 factors compared.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease. The company also provides interventional access products that are used in dialysis, oncology, and critical care therapies; and cardiac care products, such as diagnostic and intra-aortic balloon catheters, and capital equipment. In addition, it offers anesthesia products, such as pain management products for use in surgical and obstetric procedures; airway management products and related devices for use in pre-hospital emergency and hospital settings; and other pre-hospital emergency products. Further, the company offers surgical products, including Weck Ligation Systems, Weck EFx Fascial Closure Systems, Percutaneous Surgical Systems, Weck Vista bladeless access ports, Deknatel sutures, and Pilling and Kmedic surgical instruments; products for use in acute care settings for diagnostic and therapeutic procedures, and in general and specialty surgical applications; and single-use respiratory, urology, and interventional urology products. Additionally, it provides devices and instruments for other medical device manufacturers, such as custom-engineered extrusions, diagnostic and interventional catheters, balloon sheath/dilator sets and kits, sutures, performance fibers, and bioresorbable resins and fibers. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was founded in 1943 and is headquartered in Wayne, Pennsylvania.

Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply